שווי פעילות לרווח לפני ריבית, מסים ופחת 23andMe (ME)

23andMe Holding Co. (ME) is developing a hybrid model, combining direct sales of genetic tests with partnerships in pharmaceutical development. The company brings together leading data scientists and geneticists passionate about the concepts of personalized medicine. The stock price history reflects an EV/EBITDA ratio of . The business relies on its own product cycle, which makes it resilient to global economic fluctuations and transforms it into a defensive asset.

The crisis of pricing power and falling demand for DNA tests at 23andMe Holding Co. (ME) make business valuation via EV/EBITDA critically important. This multiple relates the total value of the company to its operating profit before depreciation and taxes, revealing the real resilience of capital against debt. Analyzing the history of the business's EV/EBITDA ratio allows for the determination of the asset's degree of overvaluation amid deep losses and a high risk of default.